Role of Interleukin-1β and Prostaglandin E2 in Prediction and Outcome of Apnea in Neonates (NCT06827197) | Clinical Trial Compass
CompletedNot Applicable
Role of Interleukin-1β and Prostaglandin E2 in Prediction and Outcome of Apnea in Neonates
Egypt100 participantsStarted 2023-05-01
Plain-language summary
Our thesis proposed that IL-1β may affect brainstem respiratory control via prostaglandin-dependant mechanism so we investigated the mediator roles of IL-1β and PGE2 levels in predicting apnea in pretertm newborn and their relation to clinical outcomes.
Who can participate
Age range1 Day – 2 Months
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Preterm infants born at less than 37 weeks of gestation.
* Neonates aged from birth up to 28 days.
* Neonates diagnosed with apnea of prematurity or exhibiting apneic episodes
Exclusion Criteria:
* Full-term neonates.
* Neonates with major congenital malformations or genetic syndromes.
* Neonates with severe neurological impairments (e.g., intraventricular hemorrhage grade III or IV).
* Neonates with confirmed or suspected sepsis or active infections.
* Neonates receiving steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or other medications known to alter interleukin-1β or prostaglandin E2 levels.
* Neonates with congenital heart diseases.
* Neonates with a history of significant birth asphyxia requiring extensive resuscitation.
* Neonates whose parents or guardians refuse to provide informed consent.